{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-014880","form_type":"8-K","ticker":"MNPR","cik":"0001645469","company_name":"Monopar Therapeutics","filed_at":"2025-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.180296+00:00","generated_at":"2026-05-22T08:17:58.857638+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Monopar presents ALXN1840 late-breaker data at EASL showing sustained efficacy and safety over 2.6 years","bullets":["Pooled analysis from three trials (n=255) shows sustained improvements in UWDRS Part II/III and copper mobilization.","Fewer than 5% of patients had a drug-related serious adverse event; no renal/urinary SAEs reported.","ALXN1840 improved CGI-I and New Wilson Index vs. standard of care; patients reported higher convenience.","Median treatment duration 961 days (efficacy) and 943.5 days (safety) across four trials."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-014880","json":"https://secwatch.observer/filing/0001437749-25-014880.json","markdown":"https://secwatch.observer/filing/0001437749-25-014880.md","text":"https://secwatch.observer/filing/0001437749-25-014880.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645469/000143774925014880/0001437749-25-014880-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645469/000143774925014880/mnpr20250505_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T08:17:58.857638+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}